FDA Approves Tudriqev for Advanced Refractory Melanoma
Silver Spring, Maryland, USA, August 8, 2026 The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
PD-1 inhibitor
Advertisement
Genentech FDA Filing Advances Lunsumio-Polivy in LBCL
SOUTH SAN FRANCISCO, Calif., June 17, 2026 Genentech, a member of the Roche Group, has reached a significant regulatory...
Mabwell Showcases Strong 9MW2821 Cervical Cancer Data
COPENHAGEN, Denmark, June 18, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, has unveiled encouraging...
Regeneron Pharmaceuticals Melanoma Trial Misses Primary PFS Goal
TARRYTOWN, New York, May 15, 2026 Regeneron Pharmaceuticals announced updated results from its Phase 3 melanoma trial evaluating the...
LOQTORZI + Chemo Nearly Doubles Survival in NPC at Six Years
REDWOOD CITY, Calif., December 8, 2025 — Coherus Oncology today announced compelling six-year overall survival (OS) follow-up data from...
Advertisements
Junshi Biosciences Phase 3 Trial Confirms JS001sc Success in NSCLC
SHANGHAI, China, Nov. 25, 2025 — Junshi Biosciences announced that its Phase 3 clinical study evaluating JS001sc, a subcutaneous...
Advertisement
